Left ventricular hypertrophy regression: the LIVE trial

D J Sheridan1

  • 1Academic Cardiology Unit, Division of NHLI, Imperial College School of Medicine, St Mary's Hospital, Queen Elizabeth the Queen Mother Wing, London W2 1NY, UK.

Cardiologia (Rome, Italy)
|December 25, 2002
PubMed

Insights

The LIVE study found that indapamide effectively reduced left ventricular hypertrophy (LVH) in hypertensive patients over one year. This diuretic demonstrated efficacy comparable to enalapril in LVH regression.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Left ventricular hypertrophy (LVH) increases vascular event risk.
  • Diuretic efficacy for LVH reduction is debated.
  • Antihypertensive treatments are evaluated for LVH regression.

Purpose of the Study:

  • To compare indapamide versus enalapril for LVH regression in hypertensive patients.
  • To assess the efficacy of indapamide 1.5 mg daily and enalapril 20 mg daily.
  • To evaluate LVH reduction after one year of treatment.

Main Methods:

  • Prospective, double-blind, randomized controlled trial (LIVE study).
  • Inclusion criteria: Hypertensive patients with LVH.
  • Echocardiography used for LVH assessment, with blind reading by an independent committee.

Main Results:

  • Preliminary data confirm indapamide's antihypertensive efficacy.
  • Indapamide showed efficacy in reducing left ventricular mass.
  • Progressive LVH reduction observed over one year with indapamide.

Conclusions:

  • Indapamide is effective in reducing left ventricular hypertrophy in hypertensive patients.
  • The study provides evidence for indapamide's role in managing LVH.
  • Indapamide offers a viable treatment option for hypertensive patients with LVH.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...